跳至主要内容
临床试验/NCT07598214
NCT07598214招募中4 期

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

Beni-Suef University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年2月3日最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
100
试验地点
1

研究概览

简要总结

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

详细描述

The current study is a prospective randomized controlled clinical study that will be conducted on about 100 cancer patients.

Study duration The study will be conducted from January 2025 to September 2025

Study population Group I (control): includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy.

Group II (Test group) includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy plus 450 mg diosmin and 50 mg hesperidin combination orally twice daily.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

排除标准

  • -History of allergic reactions attributed to drugs in the study.
  • Pregnant women.
  • Life expectancy less than 6 months
  • Inability or unwillingness to comply with research protocols.
  • Cancer patients with impaired renal function (creatinine clearance < 50 mL/min)
  • Preexisting hearing loss.
  • Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hasnaa Osama

lecturer

Beni-Suef University

研究点 (1)

Loading locations...

相似试验